Mayinglong Pharmaceutical Group Co., Ltd.

XSSC:600993 Stock Report

Market Cap: CN¥11.3b

Mayinglong Pharmaceutical Group Past Earnings Performance

Past criteria checks 3/6

Mayinglong Pharmaceutical Group has been growing earnings at an average annual rate of 6.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 5.7% per year. Mayinglong Pharmaceutical Group's return on equity is 12%, and it has net margins of 13.9%.

Key information

6.1%

Earnings growth rate

6.1%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate5.7%
Return on equity12.0%
Net Margin13.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Mayinglong Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSSC:600993 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,48248297272
30 Jun 243,42447492468
31 Mar 243,25945387469
31 Dec 233,13744382969
30 Sep 233,19448193067
30 Jun 233,24548893871
31 Mar 233,41652990677
31 Dec 223,53247989678
30 Sep 223,64051383879
30 Jun 223,64448284972
31 Mar 223,47348582970
31 Dec 213,38546582167
30 Sep 213,58745778368
30 Jun 213,47943979470
31 Mar 213,31742778260
31 Dec 202,79241967856
30 Sep 202,51839663954
30 Jun 202,41137861451
31 Mar 202,43133659753
31 Dec 192,70536066355
30 Sep 192,52834967845
30 Jun 192,40029065844
31 Mar 192,31124163541
31 Dec 182,19817662241
30 Sep 182,15220561043
30 Jun 182,04124857861
31 Mar 181,86130256249
31 Dec 171,75132055538
30 Sep 171,88427953328
30 Jun 171,9372665380
31 Mar 172,0132575250
31 Dec 162,1032505100
30 Sep 161,9242454990
30 Jun 161,8932384750
31 Mar 161,8332304800
31 Dec 151,7842234820
30 Sep 151,7392074760
30 Jun 151,6572154700
31 Mar 151,6422034800
31 Dec 141,6212014740
30 Sep 141,6072054890
30 Jun 141,6231994810
31 Mar 141,6051884820
31 Dec 131,6021864830

Quality Earnings: 600993 has high quality earnings.

Growing Profit Margin: 600993's current net profit margins (13.9%) are lower than last year (15.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 600993's earnings have grown by 6.1% per year over the past 5 years.

Accelerating Growth: 600993's earnings growth over the past year (0.3%) is below its 5-year average (6.1% per year).

Earnings vs Industry: 600993 earnings growth over the past year (0.3%) exceeded the Pharmaceuticals industry -2.5%.

Return on Equity

High ROE: 600993's Return on Equity (12%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 04:09
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mayinglong Pharmaceutical Group Co., Ltd. is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jun LiuChangjiang Securities Co. LTD.
Ling Bo TuChina Minzu Securities
Bing ZhaoChina Renaissance Securities